Triple

T5248760
Position Surface form Disambiguated ID Type / Status
Subject AstraZeneca E118527 entity
Predicate notableProduct P1448 FINISHED
Object Tagrisso
Tagrisso is a targeted cancer therapy (osimertinib) used primarily to treat certain types of EGFR-mutated non-small cell lung cancer.
 E505479 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Tagrisso | Statement: [AstraZeneca, notableProduct, Tagrisso]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Tagrisso
Context triple: [AstraZeneca, notableProduct, Tagrisso]
  • A. Keytruda
    Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
  • B. Ibrance
    Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
  • C. Verzenio
    Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
  • D. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • E. Inflectra
    Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Tagrisso
Triple: [AstraZeneca, notableProduct, Tagrisso]
Generated description
Tagrisso is a targeted cancer therapy (osimertinib) used primarily to treat certain types of EGFR-mutated non-small cell lung cancer.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Tagrisso
Target entity description: Tagrisso is a targeted cancer therapy (osimertinib) used primarily to treat certain types of EGFR-mutated non-small cell lung cancer.
  • A. Keytruda
    Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
  • B. Ibrance
    Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
  • C. Verzenio
    Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
  • D. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • E. Inflectra
    Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69bd4468aacc8190a8196f71855cdf4f completed March 20, 2026, 12:58 p.m.
NER Named-entity recognition batch_69bd7b787b34819081af96de9355bb4f completed March 20, 2026, 4:53 p.m.
NED1 Entity disambiguation (via context triple) batch_69bef83998f881909fef2746f5c496af completed March 21, 2026, 7:57 p.m.
NEDg Description generation batch_69befa746be88190a8d807317ab36430 completed March 21, 2026, 8:07 p.m.
NED2 Entity disambiguation (via description) batch_69befac54e8c8190986aca0f5591d04e completed March 21, 2026, 8:08 p.m.
Created at: March 20, 2026, 1:50 p.m.